Optimisation et caractérisation d'un modèle d'ischémie focale du noyau accumbens chez la souris

Authors: Bouchard, Jonathan
Advisor: Ménard, Caroline
Abstract: Problematic: One-third of stroke survivors develop post-stroke depression. Stroke of the basal ganglia has been linked to increased post-stroke depression. The nucleus accumbens, an important brain region in reward and in the regulation of emotions, is part of the basal ganglia. Alterations of the nucleus accumbens contribute to depression, but very few studies have investigated this brain region in the context of post-stroke depression. Hypothesis: An ischemic lesion affecting primarily the left nucleus accumbens will cause or will amplify the depressive phenotype of male mice. Methods: Endothelin-1, a vasoconstrictive peptide, was injected in the left nucleus accumbens. The lesion has been characterized on a morphological level (cresyl violet and immunohistochemistry) and on a molecular level (RT-qPCR) at different times. Behavioral tests have been done to possibly show the depressive phenotype of mice. Results: The endothelin-1 injection in the left nucleus accumbens of mice induces a lesion that presents a typical ischemic cellular response, and its volume is significant until 2-weeks post-surgery. Left nucleus accumbens shows impressive molecular changes that seem to be related to angiogenesis and that reach their peak at 2 weeks. Even with these lesion characteristics, the lesion does not induce a depressive phenotype in mice with or without a mild social stress, a microdefeat, after the surgery. Conclusion: This present model is an ischemic model of the nucleus accumbens, but it is not a model of post-stroke depression.
Document Type: Mémoire de maîtrise
Issue Date: 2022
Open Access Date: 20 June 2022
Permalink: http://hdl.handle.net/20.500.11794/73613
Grantor: Université Laval
Collection:Thèses et mémoires

Files in this item:
Description SizeFormat 
38145.pdf4.65 MBAdobe PDFThumbnail
All documents in CorpusUL are protected by Copyright Act of Canada.